Health Care · Biological Products, (No Diagnostic Substances) · OTC · CIK 72444 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.47Day −2.06%Mkt cap $114MP/E (FY) 6.7×1Y +17.5%Off 52W high −44.0%Vol (1Y) 90.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,124 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$0.63 |
| Implied upside+34.7% |
| Valuation confidenceLOW |
| Price impliesUNDEMANDING · −12.4% growth |
| Short interest1.1% of sh out |
| Days to cover4.3d |
| 13F net flow (QoQ)+0.00% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-07 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)6.7× |
| Sales (TTM)$255.6M |
| YTD+34.3% |
| 1Y+17.5% |
| 3Y−42.5% |
| 5Y−94.0% |
| Since incept. (ann.)−29.3% |
Total return through 2026-07-29 · series begins 2018-02-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)90.3% |
| Ann. volatility (3Y)96.4% |
| Sharpe (1Y)0.59 |
| Sharpe (3Y)0.29 |
| Max drawdown (1Y)−43.7% |
| Max drawdown (3Y)−78.7% |
| Beta (3Y vs SPY)1.59 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Heritage Wealth Advisors | 29,655 | $17,941 | 0.01% | +14.1% |
| LVM CAPITAL MANAGEMENT LTD/MI | 25,000 | $15,000 | 0.01% | +0.0% |
| Ascentis Independent Advisors | 2,000 | $1,210 | 0.00% | new |
| First Command Advisory Services, Inc. | 40 | $24 | 0.00% | new |
| Archer Investment Corp | 15 | $9 | 0.00% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.02 | — | $39.2M | +87.9% |
| 2025-12-31 | 2026-03-12 | — | — | $104.2M | +586.5% |
| 2025-09-30 | 2025-11-13 | — | — | $72.4M | +1367.9% |
| 2025-06-30 | 2025-08-13 | — | — | $39.7M | +520.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Government Contract 95% · License 4% · Collaboration Revenue 1% · Non Cash Royalty Revenue 1%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Earnings (TTM)$37.1M |
| ROE22.3% |
| Net margin6.9% |
| Sales growth 3Y1204.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
